Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations
Source abstract
Abstract
Adenoviruses show promising potential as vectors for cancer vaccines, however, their high immunogenicity can be problematic when it comes to homologous prime-boost strategies. In the studies presented here we show that heterologous prime-boost vaccinations involving ovalbumin (OVA)-antigen-coated microparticles as a prime, and adenovirus encoding OVA (AdOVA) as a boost, were equally as effective as homologous AdOVA prime-boosts at generating OVA-specific CD8(+) T-cell responses, which translated into effective tumor protection. OVA-coated biodegradable poly α-hydroxy acid-based microparticles of varying chemistries, when used as primes in heterologous prime-boost vaccinations, were comparable in terms of promoting OVA-specific CD8(+) T cells as well as providing protection against subsequent tumor challenge. These findings auger well for using poly α-hydroxy acid-based microparticles in prime-boost viral vaccination strategies geared toward the safer, and potentially more efficient, generation of anti-tumor immunity.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Virus-based gene therapy research · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Therapeutic cancer vaccines: current status and moving forward10.1093/jnci/djs033 ↗
2. Generation of tumor-specific T-cell therapies10.1016/j.blre.2005.05.001 ↗
3. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes10.1016/S0065-230X(08)60294-8 ↗
4. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies10.1111/j.1600-065X.1999.tb01326.x ↗
5. The prime-boost strategy: exciting prospects for improved vaccination10.1016/S0167-5699(00)01612-1 ↗
6. Jump-starting the immune system: prime-boosting comes of age10.1016/j.it.2003.11.009 ↗
7. Strategies and implications for prime-boost vaccination to generate memory CD8 T cells10.1007/978-1-4419-5632-3_7 ↗
8. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly10.1073/pnas.1004661107 ↗
9. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors10.1002/ijc.1556 ↗
10. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix10.4049/jimmunol.166.2.731 ↗
11. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer10.1016/j.vaccine.2006.04.022 ↗
12. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine10.1002/ijc.22873 ↗
13. Development of an MHC class I L(d)-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse10.1038/pcan.2010.57 ↗
14. Chitosan is a surprising negative modulator of cytotoxic CD8(+) T cell responses elicited by adenovirus cancer vaccines10.1021/mp100464y ↗
15. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN10.1007/s00262-011-1038-y ↗
16. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results10.1158/1078-0432.CCR-09-1910 ↗
17. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses
18. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen10.1016/j.vaccine.2009.05.017 ↗
19. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression10.1016/j.vaccine.2010.12.016 ↗
20. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model10.1007/s00262-012-1296-3 ↗
21. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients10.1073/pnas.1117208109 ↗
22. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer10.1016/j.vaccine.2012.09.001 ↗
23. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy10.1053/j.seminoncol.2012.02.013 ↗
24. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro10.1016/S0264-410X(02)00521-2 ↗
25. pH-triggered microparticles for peptide vaccination10.4049/jimmunol.173.4.2578 ↗
26. Delivery of tumor antigens to dendritic cells using biodegradable microspheres
27. Oral microparticulate vaccine for melanoma using M-cell targeting10.3109/1061186X.2011.622395 ↗
28. Formulation and evaluation of a particulate oral breast cancer vaccine10.1002/jps.23275 ↗
29. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo10.1016/j.jconrel.2008.04.014 ↗
30. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow10.1016/S0022-1759(98)00204-X ↗
31. Analysis of poly(d, l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro10.1023/A:1020452531828 ↗
32. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells10.1023/B:PHAM.0000033012.16152.5d ↗
33. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles
34. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma10.1007/s00262-008-0574-6 ↗
35. Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity10.1016/j.nano.2010.03.001 ↗
36. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres10.1016/S0928-0987(01)00218-4 ↗
37. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine10.1021/mp100255c ↗
38. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer10.1016/j.addr.2008.12.005 ↗
39. Modifying adenoviral vectors for use as gene-based cancer vaccines10.1089/0882824041310603 ↗
40. Current advances and future challenges in adenoviral vector biology and targeting10.2174/156652307780859062 ↗
41. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients10.1002/jgm.1565 ↗
42. Hydrophilic poly(dl-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells10.1016/S0168-3659(01)00413-8 ↗
43. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control10.1002/eji.200939543 ↗